Validation of Recombinant Heparan Sulphate Reagents for CNS Repair.

Turnbull, Jeremy

Abstract

Therapies that target the multicellular pathology of central nervous system (CNS) disease/injury are urgently required. Modified non-anticoagulant heparins mimic the heparan sulphate (HS) glycan family and have been proposed as therapeutics for CNS repair since they are effective regulators of numerous cellular processes. Our in vitro studies have demonstrated that low-sulphated modified heparan sulphate mimetics (LS-mHeps) drive CNS repair. However, LS-mHeps are derived from pharmaceutical heparin purified from pig intestines, in a supply chain at risk of shortages and contamination. Alternatively, cellular synthesis of heparin and HS can be achieved using mammalian cell multiplex genome engineering, providing an alternative source of recombinant HS mimetics (rHS). TEGA Therapeutics (San Diego) have manufactured rHS reagents with varying degrees of sulphation and we have validated their ability to promote repair in vitro using models that mimic CNS injury, making comparisons to LS-mHep7, a previous lead compound. We have shown that like LS-mHep7, low-sulphated rHS compounds promote remyelination and reduce features of astrocytosis, and in contrast, highly sulphated rHS drive neurite outgrowth. Cellular production of heparin mimetics may, therefore, offer potential clinical benefits for CNS repair.

Citation

Turnbull, J. (2023). Validation of Recombinant Heparan Sulphate Reagents for CNS Repair. Biology, 12(3), Article 407. https://doi.org/10.3390/biology12030407

• Acceptance Date: Mar 2, 2023
• Publication Date: Mar 4, 2023
• Journal: Biology (Basel)
• Print ISSN: 2079-7737
• Publisher: MDPI
• Volume: 12
• Issue: 3
• Article Number: 407
• DOI: https://doi.org/10.3390/biology12030407
• Keywords: heparan sulphate; recombinant heparin mimetics; CNS repair; remyelination; neurite outgrowth
• Public URL: https://keele-repository.worktribe.com/output/426985
• Publisher URL: https://www.mdpi.com/2079-7737/12/3/407
• Additional Information: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).